guest ::
| Home > Publications database > Anthropometric and blood parameters for the prediction of NAFLD among overweight and obese adults. > print |
| Home > Publications database > Anthropometric and blood parameters for the prediction of NAFLD among overweight and obese adults. > print |
| 001 | 136752 | ||
| 005 | 20240229105056.0 | ||
| 024 | 7 | _ | |a 10.1186/s12876-018-0840-9 |2 doi |
| 024 | 7 | _ | |a pmid:30005625 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC6045848 |2 pmc |
| 024 | 7 | _ | |a altmetric:46601536 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2018-01190 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kühn, Tilman |0 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Anthropometric and blood parameters for the prediction of NAFLD among overweight and obese adults. |
| 260 | _ | _ | |a London |c 2018 |b BioMed Central |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1536312934_14253 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Non-alcoholic fatty liver disease (NAFLD) comprises non-progressive steatosis and non-alcoholic steatohepatitis (NASH), the latter of which may cause cirrhosis and hepatocellular carcinoma (HCC). As NAFLD detection is imperative for the prevention of its complications, we evaluated whether a combination of blood-based biomarkers and anthropometric parameters can be used to predict NAFLD among overweight and obese adults.143 overweight or obese non-smokers free of diabetes (50% women, age: 35-65 years) were recruited. Anthropometric indices and routine biomarkers of metabolism and liver function were measured to predict magnetic resonance (MR) - derived NAFLD by multivariable logistic regression models. In addition, we evaluated to which degree the use of more novel biomarkers (adiponectin, leptin, resistin, C-reactive protein, TNF-α, IL-6, IL-8 and interferon-γ) could improve prediction models.NAFLD was best predicted by a combination of age, sex, waist circumference, ALT, HbA1c, and HOMA-IR at an area under the receiver operating characteristic curve (AUROC) of 0.87 (95% CI: 0.81, 0.93) before and 0.85 (95% CI: 0.78, 0.91) after internal bootstrap validation. The use of additional biomarkers of inflammation and metabolism did not improve NAFLD prediction. Previously published indices predicted NAFLD at AUROCs between 0.71 and 0.82.The AUROC of > 0.8 obtained by our regression model suggests the feasibility of a non-invasive detection of NAFLD by anthropometry and circulating biomarkers, even though further increments in the capacity of prediction models may be needed before NAFLD indices can be applied in routine clinical practice. |
| 536 | _ | _ | |a 313 - Cancer risk factors and prevention (POF3-313) |0 G:(DE-HGF)POF3-313 |c POF3-313 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Nonnenmacher, Tobias |b 1 |
| 700 | 1 | _ | |a Sookthai, Disorn |0 P:(DE-He78)fd4ffe2a3f08e0158b82400acd6716be |b 2 |u dkfz |
| 700 | 1 | _ | |a Schübel, Ruth |0 P:(DE-He78)ceb74219d144ab5760a228e71440c5ca |b 3 |u dkfz |
| 700 | 1 | _ | |a Quintana Pacheco, Daniel Antonio |0 P:(DE-He78)2b1939dd3b00e62eeea7798367576c30 |b 4 |u dkfz |
| 700 | 1 | _ | |a von Stackelberg, Oyunbileg |b 5 |
| 700 | 1 | _ | |a Graf, Mirja |0 P:(DE-He78)9a183bfc8348c1db81a0ecf1458d0708 |b 6 |u dkfz |
| 700 | 1 | _ | |a Johnson, Theron Scot |0 P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa |b 7 |u dkfz |
| 700 | 1 | _ | |a Schlett, Christopher L |b 8 |
| 700 | 1 | _ | |a Kirsten, Romy |0 P:(DE-He78)94b37a09583db23ab2d40029b2c6e0b3 |b 9 |u dkfz |
| 700 | 1 | _ | |a Ulrich, Cornelia M |b 10 |
| 700 | 1 | _ | |a Kaaks, Rudolf |0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |b 11 |u dkfz |
| 700 | 1 | _ | |a Kauczor, Hans-Ulrich |b 12 |
| 700 | 1 | _ | |a Nattenmüller, Johanna |b 13 |
| 773 | _ | _ | |a 10.1186/s12876-018-0840-9 |g Vol. 18, no. 1, p. 113 |0 PERI:(DE-600)2041351-8 |n 1 |p 113 |t BMC gastroenterology |v 18 |y 2018 |x 1471-230X |
| 909 | C | O | |o oai:inrepo02.dkfz.de:136752 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)fd4ffe2a3f08e0158b82400acd6716be |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)ceb74219d144ab5760a228e71440c5ca |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)2b1939dd3b00e62eeea7798367576c30 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)9a183bfc8348c1db81a0ecf1458d0708 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)94b37a09583db23ab2d40029b2c6e0b3 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |2 G:(DE-HGF)POF3-300 |v Cancer risk factors and prevention |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2018 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BMC GASTROENTEROL : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l Epidemiologie von Krebserkrankungen |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)G110-20160331 |k G110 |l Präventive Onkologie |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G110-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|